DRG Market Assessment reports

Clarivate Epidemiology’s coverage of monoclonal gammopathy of undetermined significance (MGUS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical…

The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment duration. The availability of premium-priced branded agents prescribed…

Clarivate Epidemiology’s coverage of primary immune thrombocytopenic purpura (ITP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…

Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key hemophilia A patient population covering 171 countries and more than…

Clarivate Epidemiology’s coverage of myelodysplastic syndromes (MDS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key MDS patient populations, covering 171 countries and more than 99% of…

Clarivate Epidemiology’s coverage of myelodysplastic syndromes (MDS) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed…

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that leads to a decrease in platelet production, thus increasing the risk of bleeding. Current therapies for ITP can be broadly…

Clarivate Epidemiology’s coverage of acute lymphoblastic leukemia (ALL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of acute lymphoblastic leukemia (ALL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…